Replies to post #226245 on Biotech Values

[jbog]

Enanta downgraded to Underweight from Neutral at JPMorgan

JPMorgan analyst Eric Joseph downgraded Enanta Pharmaceuticals to Underweight from Neutral and lowered his price target for the shares to $57 from $86.

Read more at:
https://thefly.com/landingPageNews.php?id=2968060